Goldman Sachs
DFTX

Goldman Sachs’s Definium Therapeutics DFTX Stock Holding History

Goldman Sachs’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-39,547
Closed -$1.38M – 6605
2021
Q3 		$1.38M Buy
+39,547
New +$1.71M ﹤0.01% 4500

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs's DFTX Position: Q2 2026 in Review

Goldman Sachs increased its Definium Therapeutics (DFTX) stake by 7.5% in Q2 2026, buying an estimated $3.1M and bringing the position to 1,800,852 shares worth $84.7M. The position accounts for 0.01% of the portfolio, ranked #1361.

Goldman Sachs first reported a position in DFTX in Q2 2021 and has held it in 21 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Goldman Sachs held 1,800,852 shares of Definium Therapeutics worth $84.7M as of Q2 2026.
  • Goldman Sachs bought 125,441 Definium Therapeutics shares in Q2 2026, an estimated $3.1M.
  • Definium Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1361 holding.
  • Goldman Sachs first reported a position in Definium Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.